Viviana Simon

Summary

Affiliation: Aaron Diamond AIDS Research Center
Country: USA

Publications

  1. pmc Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 77:7736-45. 2003
  2. ncbi request reprint Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals
    Michael Louie
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    AIDS 17:1151-6. 2003
  3. ncbi request reprint Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication
    Bharat Ramratnam
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 35:33-7. 2004
  4. ncbi request reprint Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience
    Anita Shet
    Aaron Diamond AIDS Research Center an affiliate of the Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 41:439-46. 2006
  5. ncbi request reprint Determining the relative efficacy of highly active antiretroviral therapy
    Michael Louie
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, NY 10016, USA
    J Infect Dis 187:896-900. 2003
  6. pmc The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H
    Mawuena Binka
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USA
    J Virol 86:49-59. 2012
  7. ncbi request reprint Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York 1016, USA
    AIDS 16:1511-9. 2002
  8. ncbi request reprint HIV-1 dynamics in vivo: implications for therapy
    Viviana Simon
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nat Rev Microbiol 1:181-90. 2003
  9. ncbi request reprint Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Infect Dis 186:634-43. 2002
  10. pmc The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity
    Marcel Ooms
    Division of Infectious Diseases, Department of Medicine, and Department of Microbiology, Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Virol 84:7961-9. 2010

Collaborators

Detail Information

Publications23

  1. pmc Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Avenue, 7th Floor, New York, NY 10016, USA
    J Virol 77:7736-45. 2003
    ..Further studies are needed to elucidate the precise regions that are essential for these characteristics...
  2. ncbi request reprint Determining the antiviral activity of tenofovir disoproxil fumarate in treatment-naive chronically HIV-1-infected individuals
    Michael Louie
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, NY 10016, USA
    AIDS 17:1151-6. 2003
    ..To assess the efficacy of tenofovir disoproxil fumarate (TDF) monotherapy by following the initial rate of decline in plasma viral load, which is a measure of the efficacy of therapy in blocking viral replication...
  3. ncbi request reprint Intensification of antiretroviral therapy accelerates the decay of the HIV-1 latent reservoir and decreases, but does not eliminate, ongoing virus replication
    Bharat Ramratnam
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    J Acquir Immune Defic Syndr 35:33-7. 2004
    ..Additional studies are needed to understand the host- and pathogen-related determinants of incomplete pharmacologic control of HIV-1 replication...
  4. ncbi request reprint Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience
    Anita Shet
    Aaron Diamond AIDS Research Center an affiliate of the Rockefeller University, New York, NY 10016, USA
    J Acquir Immune Defic Syndr 41:439-46. 2006
    ....
  5. ncbi request reprint Determining the relative efficacy of highly active antiretroviral therapy
    Michael Louie
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, New York, NY 10016, USA
    J Infect Dis 187:896-900. 2003
    ..Nevertheless, we believe that optimal treatment regimens for HIV-1 have yet to be identified and that continued research to achieve this goal is warranted...
  6. pmc The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H
    Mawuena Binka
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USA
    J Virol 86:49-59. 2012
    ....
  7. ncbi request reprint Evolving patterns of HIV-1 resistance to antiretroviral agents in newly infected individuals
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York 1016, USA
    AIDS 16:1511-9. 2002
    ..To assess temporal changes in prevalence of transmitted HIV-1 drug resistance in a homogeneous cohort of newly infected individuals...
  8. ncbi request reprint HIV-1 dynamics in vivo: implications for therapy
    Viviana Simon
    Aaron Diamond AIDS Research Center, Rockefeller University, 455 First Avenue, New York, New York 10016, USA
    Nat Rev Microbiol 1:181-90. 2003
    ..We also discuss the obstacles that result from the ability of HIV-1 to remain dormant for a prolonged period of time in a subset of long-lived cells, despite an apparently effective antiretroviral treatment...
  9. ncbi request reprint Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination
    Martin Markowitz
    Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York 10016, USA
    J Infect Dis 186:634-43. 2002
    ....
  10. pmc The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity
    Marcel Ooms
    Division of Infectious Diseases, Department of Medicine, and Department of Microbiology, Global Health and Emerging Pathogens Institute, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Virol 84:7961-9. 2010
    ..Thus, the antiviral activity of A3H haplotypes is determined by its incorporation into the viral core, in proximity to the reverse transcription complex...
  11. pmc HIV/AIDS epidemiology, pathogenesis, prevention, and treatment
    Viviana Simon
    Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, USA
    Lancet 368:489-504. 2006
    ..This Seminar provides an update on epidemiology, pathogenesis, treatment, and prevention interventions pertinent to HIV-1...
  12. pmc APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1
    Marcel Ooms
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York, USA
    J Virol 86:6097-108. 2012
    ..Taken together, our data indicate that HTLV-1 is a likely target for multiple A3 proteins...
  13. pmc Moderate influence of human APOBEC3F on HIV-1 replication in primary lymphocytes
    Lubbertus C F Mulder
    Mount Sinai School of Medicine, Department of Medicine, The Global Health and Emerging Pathogens Institute, New York, New York 10029, USA
    J Virol 84:9613-7. 2010
    ..Lastly, the endogenous A3F mRNA and protein expression levels in PBMCs were considerably lower than those of A3G. Our results suggest that A3F neutralization is dispensable for HIV-1 replication in primary human T-lymphocytes...
  14. pmc The resistance of human APOBEC3H to HIV-1 NL4-3 molecular clone is determined by a single amino acid in Vif
    Marcel Ooms
    Department of Microbiology, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e57744. 2013
    ..These studies provide an explanation for the conflicting reports regarding A3H resistance to Vif mediated degradation...
  15. ncbi request reprint Progestin-based contraceptive suppresses cellular immune responses in SHIV-infected rhesus macaques
    Nataliya Trunova
    Aaron Diamond AIDS Research Center, The Rockefeller University, 455 First Ave, 7th Floor, New York, NY 10016, USA
    Virology 352:169-77. 2006
    ....
  16. pmc Characterization of HIV-1 integrase N-terminal mutant viruses
    Aliza G Lloyd
    The Aaron Diamond AIDS Research Center 455 First Avenue, New York, NY 10016, USA
    Virology 360:129-35. 2007
    ..We propose that the severe deficiency of these mutants exert a strong selective pressure that leads to the near total conservation of the N-terminal residue of integrase in HIV-1, HIV-2 and SIV...
  17. pmc Cytidine deamination induced HIV-1 drug resistance
    Lubbertus C F Mulder
    Department of Medicine, Division of Infectious Diseases, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1090, New York, NY 10029, USA
    Proc Natl Acad Sci U S A 105:5501-6. 2008
    ....
  18. pmc Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling
    Juliet Morrison
    Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
    PLoS Pathog 9:e1003265. 2013
    ..Our data underscore the importance of NS5-mediated STAT2 degradation in DENV replication and identify UBR4 as a host protein that is specifically exploited by DENV to inhibit IFN-I signaling via STAT2 degradation...
  19. ncbi request reprint Identification of microRNAs of the herpesvirus family
    Sebastien Pfeffer
    Laboratory of RNA Molecular Biology, The Rockefeller University, 1230 York Avenue, Box 186, New York, New York 10021, USA
    Nat Methods 2:269-76. 2005
    ..Generally, we predicted miRNAs in several large DNA viruses, and we could neither predict nor experimentally identify miRNAs in the genomes of small RNA viruses or retroviruses...
  20. pmc Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection
    Michele Di Mascio
    Theoretical Division, Los Alamos National Laboratory, New Mexico, USA
    J Virol 78:10566-73. 2004
    ..Finally, in PHI patients the VL set point was a significant predictor of blip frequency during treatment...
  21. pmc Genetic basis of hypersusceptibility to protease inhibitors and low replicative capacity of human immunodeficiency virus type 1 strains in primary infection
    Andrew J Leigh Brown
    University of Edinburgh, Edinburgh, Scotland
    J Virol 78:2242-6. 2004
    ..This supports the view that variation in PR function is directly responsible for variation in fitness among strains in primary infection...
  22. ncbi request reprint Sustained viremia during highly active antiretroviral therapy with accelerated proviral DNA decay in the setting of infection with syphilis
    Neal Padte
    AIDS 17:2143-5. 2003
  23. pmc Origin of human immunodeficiency virus type 1 quasispecies emerging after antiretroviral treatment interruption in patients with therapeutic failure
    Gustavo H Kijak
    National Reference Center for AIDS, Department of Microbiology, School of Medicine, University of Buenos Aires, Argentina
    J Virol 76:7000-9. 2002
    ..This study demonstrates the important role that the reemergence of quasispecies plays in HIV-1 population dynamics and points out the difficulties that may be found when recycling ARV therapies with patients with treatment failure...